Prakiraan wutah bathi saben saham kanggo taun ngarep YS Biopharma Co., Ltd. (LSB)

LakeShore Biopharma Co. (LSB) ensures high margins through its network of bio-hubs and express cold-chain delivery. The next-year EPS growth estimate provided by GURU.Markets analytics confirms this trend, where 0.00 determines the current value of the metric. Market capitalization relies on the sale of anti-rabies vaccines and innovative immunizations, while optimized supply chains eliminate production disruptions.

LSB: Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep YS Biopharma 29.05.2024 - 04.10.2025

Rincian analitis perusahaan ysbiopharm.com (LSB)

- rega saham lan konsensus proyeksi valuasi:

Rega saham YS Biopharma|LSB - Target konsensus

- rincian kapitalisasi pasar:

Biji pasar LakeShore Biopharma|LSB - Total Nilai Bisnis

- informasi kapitalisasi buku:

Nilai Buku saben Saham LakeShore Biopharma|LSB - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku ysbiopharm.com|LSB - Aset Perusahaan

- indikator beban utang lan likuiditas:

Utang marang Ekuitas LakeShore Biopharma Co.|LSB - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas LakeShore Biopharma|LSB - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku LakeShore Biopharma|LSB - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan LakeShore Biopharma|Likuiditas cepet ysbiopharm.com

- informasi bathi lan kelipatan valuasi:

LSB - Bathi resik|Proyeksi bathi mangsa ngarep LakeShore Biopharma Co.|LSB - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep LakeShore Biopharma Co.|LSB - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA LakeShore Biopharma|LSB - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan LakeShore Biopharma|LSB - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan ysbiopharm.com|LSB - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep LakeShore Biopharma Co.

Analisis wiwitan perusahaan:LSB, YS Biopharma

This indicator reflects the weighted average consensus forecast for future net yield, allowing for an assessment of the business model's resilience amid macroeconomic volatility. By analyzing the projected growth of net earnings per share for year n+1, investors can track cash flow dynamics and the risks of excessive leverage. For LakeShore Biopharma Co. (LSB), the stability of this metric is supported by high capacity utilization of contract manufacturing and the absence of technological risks in vaccine production.

Pesaing wigati